{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:16:55Z","timestamp":1764688615447},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T00:00:00Z","timestamp":1153180800000},"content-version":"vor","delay-in-days":4178,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1995,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aberrant crypts are aggregates of single to multiple colonic crypts evidencing hallmarks of dysplasia and may be the earliest detectable pathological lesions for colon cancer. The aberrant crypt assay has been developed in 2 protocols. In one, putative chemoprevention agents are tested for inhibitory effects when administered concomitantly with a carcinogen. In the other, the objective of this study, aberrant crypts were induced in F344 rats by parenteral injection of the colon carcinogen azoxymeth\u2010ane (AOM) and allowed to develop for 4 weeks, when an average of 90\u2010100 aberrant crypt foci per colon were found in the methylene blue\u2010stained colon. Then, during the second 4 weeks of the experiment, aberrant crypts were allowed to further develop to a frequency of &gt; 150 foci per colon, a time when multi\u2010crypt foci were observed. During this time we tested the inhibitory effects of 4 analgesic drugs and 2 differentiation agents for effects of aberrant crypt growth and development. We found the non\u2010steroidal anti\u2010inflammatory drugs piroxicam, aspirin and ibuprofen, but not acetaminophen, to be effective in suppressing aberrant crypt formation or the progression to foci of multiple aberrant crypts. Treatment with chemo\u2010suppressing agents 13\u2010<jats:italic>cis<\/jats:italic>\u2010retinoic acid (13\u2010cRA) and 4\u2010hydroxy\u2010phenretinamide (4\u2010HPR), known differentiating agents, however, did suppress expansion of aberrant crypt foci, with 13\u2010cRA being the much more potent agent.<\/jats:p>","DOI":"10.1002\/ijc.2910600415","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T00:41:49Z","timestamp":1171932109000},"page":"515-519","source":"Crossref","is-referenced-by-count":68,"title":["Inhibition of aberrant crypt growth by non\u2010steroidal anti\u2010inflammatory agents and differentiation agents in the rat colon"],"prefix":"10.1002","volume":"60","author":[{"given":"Michael J.","family":"Wargovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Dai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.2307\/3431269"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112053252309"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501119"},{"key":"e_1_2_1_5_1","first-page":"2","article-title":"Identitication of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review","volume":"50","author":"Boone C. W.","year":"1990","journal-title":"Comer Res."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02890268"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/13.4.541"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(91)90085-V"},{"key":"e_1_2_1_9_1","first-page":"2924","article-title":"Retinoids and their receptors in differentiation. embryogenesis. and neoplasia","volume":"5","author":"De Luca L. M.","year":"1991","journal-title":"EASEBJ."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501330"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/12.12.2311"},{"key":"e_1_2_1_12_1","unstructured":"Lippman S. M.andHong W. K. 13\u2010cis\u2010retinoic acid and cancer ehemoprevention.Nat. Cancer Inst. Monogr. 111\u2013115(1992)."},{"key":"e_1_2_1_13_1","first-page":"5575","article-title":"Aspirin and the potential role of prostaglandins in colon cancer","volume":"52","author":"Marnett L. J.","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_1_14_1","first-page":"6183","article-title":"Specificity study to evaluate induc\u2010tion of aberrant crypts in murine colons","volume":"48","author":"McLellan E. A.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500129"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(87)90130-2"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(91)90073-Q"},{"key":"e_1_2_1_18_1","first-page":"1564","article-title":"Aberrant crypts: putative preneoplastic foci in human colonic mucosa","volume":"51","author":"Pretlow T. P.","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_1_19_1","first-page":"13","article-title":"Colonic aberrant crypts in azoxymethane\u2010treated F344 rats have decreased hexosaminidase activity","volume":"136","author":"Prerlow T. P.","year":"1990","journal-title":"Amer. J. Pathol."},{"key":"e_1_2_1_20_1","first-page":"5340","article-title":"Dose\u2010related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development","volume":"47","author":"Reddy B. S.","year":"1987","journal-title":"Cancer Res."},{"key":"e_1_2_1_21_1","first-page":"2562","article-title":"Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L\u2010alpha\u2010difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet","volume":"50","author":"Reddy B. S.","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/14.8.1493"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/13.6.1019"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(91)90163-J"},{"key":"e_1_2_1_25_1","first-page":"552","article-title":"Evaluation of a rat colon crypt assay to identify chemopreventive agents compared to rodent colon tumor assay systems","volume":"34","author":"Steele V. E.","year":"1993","journal-title":"Proc. Amer. Assoc. Cancer Res."},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/13.10.1863"},{"key":"e_1_2_1_27_1","first-page":"73","article-title":"Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci","volume":"73","author":"Stopera S. A.","year":"1993","journal-title":"Cytobios"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/13.11.2081"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112053252301"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501110"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910470622"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910600415","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910600415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T05:30:10Z","timestamp":1698298210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910600415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,2,8]]}},"alternative-id":["10.1002\/ijc.2910600415"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910600415","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2,8]]}}}